Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UKCTOCS.
Estrogen is a well-established risk factor for various cancers. It causes endometrial proliferation which is routinely assessed as endometrial thickness (ET) by transvaginal ultrasound (TVS). Only one study, restricted to endometrial and breast cancer, has previously considered ET and risk of a non-endometrial cancer. This study seeks to explore associations between serial ET in postmenopausal women and nine non-endometrial hormone-sensitive cancers using contemporary statistical methodology that attempts to minimize the biases typical of endogenous serial data. This was a cohort study nested within the United Kingdom Collaborative Trial for Ovarian Cancer Screening (UKCTOCS) with follow-up via linkage to national cancer registries. 50639 postmenopausal women aged 50-74 underwent annual TVS in the ultrasound arm of UKCTOCS, of whom 38105 women with a valid ET measurement, no prior hysterectomy and complete covariate data were included in this study. All were followed through linkage to national cancer registry. The effect of ET was assessed using joint models for longitudinal biomarker and time-to-event data in 6 estrogen-dependent cancers (breast, ovarian, colorectal, bladder, lung and pancreas) and Cox models for baseline ET for these 6 plus liver, gastric and non-Hodgkins lymphoma. All models were adjusted by current HRT use, BMI, age at last period, parity and OCP use. The 38105 women had a total of 267567 valid ET measurements (median=8; IQR=5-9). During 407838 total years (median=10.9) of follow-up, 1398 breast, 350 endometrial, 381 lung, 495 colorectal, 222 ovarian, 94 pancreas, 79 bladder, 62 gastric, 38 liver cancers and 52 NHLs were registered. Using joint models, a doubling of ET significantly increased risk of breast (HR=1.21; 95% CI=1.09-1.36; p=0.001), ovarian (HR=1.39; 95% CI=1.06-1.82; p=0.018) and lung (HR=1.25; 95% CI=1.02-1.54; p=0.036) cancers. There were no statistically significant associations amongst the remaining 6 cancers. Postmenopausal women with high/increasing ET are at increased risk of breast, ovarian and lung cancer. It is important that clinicians are aware of these risks as TVS is a common investigation. This article is protected by copyright. All rights reserved.